BioLineRx Ltd.
BioLineRx Ltd.
Your view on BLRX
Overview
What the company does, where it operates, and who runs it.
About BioLineRx Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Philip A. Serlin CPA, CPA, MBA
- Headquarters
- Modi’in Technology Park, Hevel Modi'in, IL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Philip A. Serlin CPA, CPA, MBA
- Headquarters
- Modi’in Technology Park, Hevel Modi'in, IL
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.
The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioLineRx Ltd., and the rating behind it. BLRX last traded at $2.51; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioLineRx Ltd.. Starting points for BioLineRx Ltd.: EPS -$0.05, beta 0.71 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioLineRx Ltd.. BioLineRx Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioLineRx Ltd.. Trailing twelve-month EPS for BioLineRx Ltd. stands at -$0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioLineRx Ltd.. BioLineRx Ltd. has reported as a listed company since 2011. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioLineRx Ltd. valued side by side against its closest peers. BioLineRx Ltd. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioLineRx Ltd., and how their positions are changing. At a $10.9M market value, institutional positions materially move BioLineRx Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioLineRx Ltd. executives and directors. Shares of BioLineRx Ltd. have traded between $2.30 and $22.40 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioLineRx Ltd.. BioLineRx Ltd. is a $10.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioLineRx Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioLineRx Ltd.. Coverage tracks BioLineRx Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.